NCT06229275

Brief Summary

This purpose of this research study is to determine the effectiveness of the Personal Pap Smear Device™ to collect adequate cervical cell samples for cytology examination when compared with the Rover Cervex-Brush (Cervix-Examination Brush).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 10, 2024

Completed
19 days until next milestone

First Posted

Study publicly available on registry

January 29, 2024

Completed
6 months until next milestone

Study Start

First participant enrolled

July 25, 2024

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 30, 2026

Completed
Last Updated

July 20, 2025

Status Verified

July 1, 2025

Enrollment Period

1.4 years

First QC Date

January 10, 2024

Last Update Submit

July 16, 2025

Conditions

Keywords

pap smear collection

Outcome Measures

Primary Outcomes (1)

  • Comparison of the samples for the Predicate Device versus PPS device

    Data of Adequate versus Inadequate will be reported to include a positive percent agreement (PPA) defined as PPA= A/(A+C) and the negative percent agreement (NPA) defined as NPA = D/(B+D) along with their 95% confidence bounds using the Clopper-Pearson method.

    Baseline

Secondary Outcomes (1)

  • The Comparison of Cell Types of the PPS Device versus the Predicate Device

    Baseline

Study Arms (2)

Pap smear collection using the Personal Pap Smear (PPS) Device

EXPERIMENTAL

The investigational device, trade named the Personal Pap Smear™ (PPS) developed by GyneConcepts of Atlanta, Georgia. It arrives completely assembled, and ready-for-use, in a sealed plastic bag. The PPS device is a multi-component assembly designed for the collection of exfoliated cervical epithelial cells. Its four major components are the (1) Tube Body, (2) U-Ring and attached Aligning Spoon, (3) Ball Handle, (with permanently anchored bristle Collection Brush), and (4) Safety Cover.

Device: Pap smear collection using the Personal Pap Smear (PPS) Device

Pap smear collection using the Rovers Cervex-Brush

ACTIVE COMPARATOR

The Predicate device utilized in this study is the Cervix-Examination Brush, manufactured by Rover (Manufacturers Code: 9443). The Cervex-Brush (CervixExamination Brush) is made of polyethylene and has a total length of 20 centimeters. The top portion uses a soft flexible brush to obtain cell samples. The brush consists of 57 semi-circular plastic bristles of various lengths. The shape is such that the top edges of the brush follow the contours of the cervix. The longer middle bristles reach deep into the endocervical canal- 'Os'. The shorter bristles touch both the ectocervical area and transformation zone at the same time. This device is packaged with identical standards used for packaging commercial tampons.

Device: Active Comparator: Pap smear collection using the Rovers Cervex-Brush

Interventions

Diagnostic Test: Use of PPS device to collect cervical cells during pap smear collection.

Pap smear collection using the Personal Pap Smear (PPS) Device

Diagnostic Test: Use of Rovers Cervex-Brush to collect cervical cells during pap smear collection.

Pap smear collection using the Rovers Cervex-Brush

Eligibility Criteria

Age21 Years - 65 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult women, aged 21-65 years old.
  • Do not have any medical or psychiatric condition affecting the ability to give voluntary informed consent.
  • Be able to read and understand English

You may not qualify if:

  • Participants currently on menses
  • Inability to provide Informed Consent
  • Previous total hysterectomy
  • History of radiation treatment for cervical cancer
  • Pregnancy
  • Medical condition that interferes with conduct of study, in investigator's opinion
  • Evidence of active cervical infection requiring treatment
  • Known bleeding diathesis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Morehouse School of Medicine

Atlanta, Georgia, 30310, United States

RECRUITING

Study Officials

  • Regina K Leonis, MD, MD

    Morehouse School of Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Regina K Leonis, MD

CONTACT

LaShawn Mays, MSM

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SCREENING
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

January 10, 2024

First Posted

January 29, 2024

Study Start

July 25, 2024

Primary Completion

December 31, 2025

Study Completion

March 30, 2026

Last Updated

July 20, 2025

Record last verified: 2025-07

Locations